LISAvienna is a joint life science platform operated by Austria Wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, it contributes to the advancement of life sciences in Vienna.
LISAvienna supports innovative biotech, pharmaceutical, medical device, and digital health companies in Vienna that develop and market new products, services, and processes. The platform links these companies with development partners and key customers.
As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers.
If you want to learn more about the Life Science Hot Spots in the center of Europe, then this episode is for you.
Join us for a colloquial chat over Life Science and Entrepreneurship.
Regeneron’s Antibody Drug Cuts Risk of Death in Some Covid-19 Patients Trial results for REGEN-COV buoy hopes that doctors could soon have a new way to tackle severe hospital cases Read more…
Bitcoin: El Salvador makes cryptocurrency legal tender El Salvador has become the first country in the world to officially classify Bitcoin as legal currency. Congress approved President Nayib Bukele's proposal to embrace the cryptocurrency, with 62 out of 84 possible votes on Tuesday night. Read more…
The Biggest Business Risks Around the World We live in an increasingly volatile world, where change is the only constant. Businesses, too, face rapidly changing environments and associated risks that they need to adapt to—or risk falling behind. These can range from supply chain issues due to shipping blockages, to disruptions from natural catastrophes. Read more…
This podcast episode will discuss the EU’s next framework program for research and innovation, Horizon Europe, and the exciting opportunities this program offers businesses, scientists, and investors. With the launch of the Horizon Europe program just weeks away, we will share insight into the program's novelties, where to start, and tips on how to be successful.
The Podcast Host, guests Kimberly Cornfield and Michael Browne will discuss questions like:
What is new in Horizon Europe? The European Innovation Council, Missions and Clusters – all you need to know
Funding for DeepTech? The opportunities for high-risk/high gain and interdisciplinary research and innovation collaboration
Where, when, and how to apply for Horizon Europe funding? – tips from the experts
We shall address all these questions and discuss the latest priorities in EU research and innovation funding and the importance of collaboration.
Our guests in this episode:
Kimberly Cornfield is Head of European Research and Innovation at University College London (UCL), one of the top-performing universities under the EU’s Horizon 2020 program, having secured ca. €400 million over the last seven years to support its research and innovation activities. To support UCL in upholding its place as one of the leading universities in the next EU research and innovation program, Horizon Europe, and achieving its impact objectives, Kimberly and her team connect scientists and business around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving their impact objectives.
Michael Browne is Director and Co-founder at Crowdhelix - an Open Innovation Platform that forges links between an international network of excellent researchers and innovating companies to help deliver pioneering collaborative projects. Michael has worked in the European Research & Innovation space for more than 15 years and is a recognized expert in Framework Programme funding.
These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!
You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren’t finding this valuable.
Nothing in this email is intended to serve as financial advice. Do your own research.